Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
ELAN · against 147 other Healthcare companies of similar size
Ranked #90 of 148 · scores higher than 38% of peers
Bars: peers in each 10-point band of the valuation score26 peers with a valuation score of 40–49, including ELAN · Click a bar to see the companies
A mix: stronger free cash flow yield and EBITDA yield, but weaker earnings yield than most Healthcare peers.
| Metric | ELAN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 146 reported | -1.7% | 2.7% | 17% | 30% | |
| EBITDA yieldHigher is better · 149 reported | 6.3% | 4.7% | 62% | 50% | |
| Free cash flow yieldHigher is better · 91 reported | 3.1% | 2.5% | 58% | 20% | |
| Book yieldHigher is better · 146 reported | 53.7% | 19.9% | 87% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 2 | 89.5B HKD (≈$11.5B) | 98 | 67 | |
| 3 | 10.4B USD | 96 | 64 | |
| 4 | 80.2B CNY (≈$11.2B) | 95 | 76 | |
| 4 | 21.5B USD | 95 | 60 | |
| 87 | 10.8B USD | 49 | 35 | |
| 87 | 32.3B AUD (≈$21.3B) | 49 | 55 | |
| 87 | 15.8B EUR (≈$17.4B) | 49 | 47 | |
| 90 | 7.2B USD | 48 | 43 | |
| 90 | 12.3B USD | 48 | 35 | |
| 90 | 18.2B USD | 48 | 40 | |
| 93 | 7.0B USD | 47 | 63 | |
| 93 | 596.9B INR (≈$7.2B) | 47 | 58 | |
| 95 | 81.4B CNY (≈$11.4B) | 46 | 55 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score